MRX-2843

N/A

Report date: 2024/04/02 11:37:50
NME

Base Information

Drug NameMRX-2843
Drug Alias NameUNC-2371UNC-2025MRX-2843
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase Mer inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Tyrosine-protein kinase Mer
Therapy Area/IndicationsSolid tumoursPathologic ProcessesNeoplasm Metastasis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesUniversity Of North Carolina At Chapel Hill
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesMeryx IncEmory UniversityBetta Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPathologic ProcessesNeoplasm Metastasis +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A